The Chinese biopharmaceutical contract manufacturing market is estimated to be worth USD 2.6 billion in 2030, predicts Roots Analysis
The growing biopharma industry in China has resulted in the creation of lucrative business opportunities for contract service providers; region-specific advantages have also attracted several foreign sponsors entities over the last few years Roots Analysis is pleased to announce the publication of its recent study, titled, “China Biopharmaceutical Contract Manufacturing Market, 2020-2030.” The report features … Continue reading The Chinese biopharmaceutical contract manufacturing market is estimated to be worth USD 2.6 billion in 2030, predicts Roots Analysis Continue Reading

